Mayne Pharma : 10/02/2022 Mayne Pharma expands US dermatology portfolio

ASX Announcement

MAYNE PHARMA EXPANDS US DERMATOLOGY PORTFOLIO

10 February 2022, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has launched an authorised generic (AG) of one of the largest dermatology products in the United States. According to IQVIA, the annual US market sales were more than US$250 million for the twelve months ending December 20211.

Mayne Pharma's CEO Scott Richards said, "This product is expected to be another important addition to our US product portfolio and be a meaningful contributor in the 2HFY22 given current competitive market dynamics. Mayne Pharma continues to expand its dermatology portfolio offering patients more affordable and accessible ways to receive their medication."

Mayne Pharma entered into a license and supply agreement with one of the largest dermatology companies to distribute this product in non-retail channels.

"This partnership further validates our ability to successfully execute on new dermatology product opportunities. Mayne Pharma has recently partnered with a number of leading pharmaceutical companies including Sandoz, Upsher Smith, Cosette, Encube and Torrent."

For further information contact:

Lisa Pendlebury (VP Investor Relations & Communications) [phone], [e-mail]

Authorised for release to the ASX by the Chair.

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide.

Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world.

Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds.

1 IQVIA, MAT Sales, December 2021